Stealth BioTherapeutics, which has been developing a rare disease drug, said it is making contingency plans to close the ...

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...